LOWELL, MA / ACCESSWIRE / June 8, 2020 / Versatope Therapeutics, Inc, a biotechnology company developing vaccines and therapeutics, announced Christopher Locher, Ph.D., CEO of Versatope Therapeutics, Inc., will present at the 2020 BIO Digital Conference being held June 8-12, 2020. Click here to view the full multimedia, interactive announcement.
- Versatope’s vesicle platform offers several advantages to vaccine development, including capturing genetic diversity, broad-scale immunologic flexibility, and favorable cost manufacturing.
- By targeting conserved regions of the influenza virus, Versatope aims to develop a one-time universal flu vaccine. Update: Intravacc and Versatope Sign Research Service Agreement to Develop Universal Influenza Vaccine Based on OMV technology.
- The Company is expanding its platform to develop a coronavirus vaccine for protection against multiple strains, including COVID-19.
Versatope’s transformational technology using synthetic biology offers the potential for strong competitive advantages for vaccine development, including capturing genetic diversity, rapid development and broad-scale immunologic flexibility. Safety, thermostability and manufacturing efficiency are additional benefits of the technology that make it unique and ideal for a pan-coronavirus vaccine and emerging pandemics.
Versatope is already advancing on the potential best-in-class universal flu vaccine and with additional funding, the company will expand into new areas beyond pandemic infectious diseases into oncology and allergy.
To learn more about how Versatope is developing a pan-coronavirus vaccine with their transformational synthetic biology technology: Get in Touch
Chief Executive Officer and Co-Founder
SOURCE: Versatope Therapeutics, Inc
View source version on accesswire.com: